Atea Pharmaceuticals (AVIR) Equity Average (2019 - 2026)

Atea Pharmaceuticals' Equity Average history runs 8 years deep, the most recent figure standing at $254.6 million for Q1 2026.

• In Q1 2026, Equity Average fell 40.1% year-over-year to $254.6 million; the TTM figure through Mar 2026 stood at $254.6 million (down 40.1% YoY), while the FY2025 annual figure was $357.2 million, down 28.14% from the prior year.
• Equity Average was $254.6 million for Q1 2026 at Atea Pharmaceuticals, down from $295.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $695.0 million in Q1 2022 to a low of $254.6 million in Q1 2026.
• Historically, Equity Average has averaged $512.8 million across 5 years, with a median of $529.8 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Equity Average increased 22.57% in 2022, then sank 40.1% in 2026.
• A 5-year view of Equity Average shows it stood at $651.9 million in 2022, then decreased by 12.8% to $568.5 million in 2023, then dropped by 21.07% to $448.7 million in 2024, then tumbled by 34.12% to $295.6 million in 2025, then fell by 13.88% to $254.6 million in 2026.
• The last three Equity Average figures came in at $254.6 million (Q1 2026), $295.6 million (Q4 2025), and $340.1 million (Q3 2025), per Business Quant data.